BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26463425)

  • 81. [Anaplastic lymphoma kinase gene abnormality and the expression of its fusion protein in primary systemic anaplastic large cell lymphoma].
    Shi YF; Liu CL; Zhou CJ; Gong LP; Dong LN; Li M; Huang X; Gao ZF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):380-6. PubMed ID: 18677384
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Non-Coding RNA Networks in ALK-Positive Anaplastic-Large Cell Lymphoma.
    Fuchs S; Naderi J; Meggetto F
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31052302
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
    Shustov A; Soma L
    Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Extra copies of ALK gene locus is a recurrent genetic aberration and favorable prognostic factor in both ALK-positive and ALK-negative anaplastic large cell lymphomas.
    Yu R; Chen G; Zhou C; Gao Z; Shi Y; Shi Y; Zhou X; Xie J; Liu H; Gong L
    Leuk Res; 2012 Sep; 36(9):1141-6. PubMed ID: 22726922
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Anaplastic large cell lymphomas with the 6p25.3 rearrangement are a heterogeneous group of tumours with a diverse molecular background.
    Díaz de la Pinta FJ; Rodríguez Moreno M; Salgado RN; Carvajal García N; Santonja C; Pérez Buira S; Piris MA; Requena L; Manso R; Rodríguez-Pinilla SM
    Hum Pathol; 2023 Jul; 137():71-78. PubMed ID: 37127078
    [TBL] [Abstract][Full Text] [Related]  

  • 86. ALK-immunoreactive neoplasms.
    Minoo P; Wang HY
    Int J Clin Exp Pathol; 2012; 5(5):397-410. PubMed ID: 22808292
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
    Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
    Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.
    Ambrogio C; Voena C; Manazza AD; Martinengo C; Costa C; Kirchhausen T; Hirsch E; Inghirami G; Chiarle R
    Cancer Res; 2008 Nov; 68(21):8899-907. PubMed ID: 18974134
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
    van der Krogt JA; Bempt MV; Ferreiro JF; Mentens N; Jacobs K; Pluys U; Doms K; Geerdens E; Uyttebroeck A; Pierre P; Michaux L; Devos T; Vandenberghe P; Tousseyn T; Cools J; Wlodarska I
    Haematologica; 2017 Sep; 102(9):1605-1616. PubMed ID: 28659337
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Fatal ALK-negative systemic anaplastic large cell lymphoma presenting with disseminated cutaneous dome-shaped papules and nodules.
    Bird JE; Leitenberger JJ; Solomon A; Blauvelt A; Hopkins S
    Dermatol Online J; 2012 May; 18(5):5. PubMed ID: 22630575
    [TBL] [Abstract][Full Text] [Related]  

  • 91. ALK-negative anaplastic large-cell lymphoma.
    Gaulard P; de Leval L
    Blood; 2016 Jan; 127(2):175-7. PubMed ID: 26769771
    [No Abstract]   [Full Text] [Related]  

  • 92. A novel model of controlling PD-L1 expression in ALK
    Zhang JP; Song Z; Wang HB; Lang L; Yang YZ; Xiao W; Webster DE; Wei W; Barta SK; Kadin ME; Staudt LM; Nakagawa M; Yang Y
    Blood; 2019 Jul; 134(2):171-185. PubMed ID: 31151983
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma.
    Ravindran A; Feldman AL; Ketterling RP; Dasari S; Rech KL; McPhail ED; Kurtin PJ; Shi M
    Am J Surg Pathol; 2021 Apr; 45(4):550-557. PubMed ID: 33165091
    [TBL] [Abstract][Full Text] [Related]  

  • 94. MicroRNA and ALK-positive anaplastic large cell lymphoma.
    Hoareau-Aveilla C; Merkel O; Meggetto F
    Front Biosci (Schol Ed); 2015 Jun; 7(2):217-25. PubMed ID: 25961697
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Recurrent
    Luchtel RA; Zimmermann MT; Hu G; Dasari S; Jiang M; Oishi N; Jacobs HK; Zeng Y; Hundal T; Rech KL; Ketterling RP; Lee JH; Eckloff BW; Yan H; Gaonkar KS; Tian S; Ye Z; Kadin ME; Sidhu J; Jiang L; Voss J; Link BK; Syrbu SI; Facchetti F; Bennani NN; Slager SL; Ordog T; Kocher JP; Cerhan JR; Ansell SM; Feldman AL
    Blood; 2019 Jun; 133(26):2776-2789. PubMed ID: 31101622
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Chimeric kinase ALK induces expression of NAMPT and selectively depends on this metabolic enzyme to sustain its own oncogenic function.
    Zhang Q; Basappa J; Wang HY; Nunez-Cruz S; Lobello C; Wang S; Liu X; Chekol S; Guo L; Ziober A; Nejati R; Shestov A; Feldman M; Glickson JD; Turner SD; Blair IA; Van Dang C; Wasik MA
    Leukemia; 2023 Dec; 37(12):2436-2447. PubMed ID: 37773266
    [TBL] [Abstract][Full Text] [Related]  

  • 97. A novel role for IL-22R1 as a driver of inflammation.
    Savan R; McFarland AP; Reynolds DA; Feigenbaum L; Ramakrishnan K; Karwan M; Shirota H; Klinman DM; Dunleavy K; Pittaluga S; Anderson SK; Donnelly RP; Wilson WH; Young HA
    Blood; 2011 Jan; 117(2):575-84. PubMed ID: 20971950
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.
    Crescenzo R; Abate F; Lasorsa E; Tabbo' F; Gaudiano M; Chiesa N; Di Giacomo F; Spaccarotella E; Barbarossa L; Ercole E; Todaro M; Boi M; Acquaviva A; Ficarra E; Novero D; Rinaldi A; Tousseyn T; Rosenwald A; Kenner L; Cerroni L; Tzankov A; Ponzoni M; Paulli M; Weisenburger D; Chan WC; Iqbal J; Piris MA; Zamo' A; Ciardullo C; Rossi D; Gaidano G; Pileri S; Tiacci E; Falini B; Shultz LD; Mevellec L; Vialard JE; Piva R; Bertoni F; Rabadan R; Inghirami G;
    Cancer Cell; 2015 Apr; 27(4):516-32. PubMed ID: 25873174
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Drivers of crizotinib resistance in ALK+ ALCL.
    Hu G; Feldman AL
    Blood; 2020 Oct; 136(14):1573-1575. PubMed ID: 33002123
    [No Abstract]   [Full Text] [Related]  

  • 100. ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma.
    Jaye DL; Feldman AL
    Blood; 2023 Apr; 141(17):2160. PubMed ID: 37103947
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.